文献速递骨软组织肉瘤与黑色素瘤

硬纤维瘤主动监测的系统综述

Active surveillance in desmoid-type fibromatosis: A systematic literature review.
PubMed 文献 · Eur J Cancer · 2020-07-29

中位进展、稳定和部分缓解百分比分别为20%、59%和19%,中位转为积极治疗的比例为29%,最常见为全身治疗(n=195)和手术(n=107)。

要点

  • AS患者中位稳定病百分比59%,进展20%,部分缓解19%。
  • 中位29%患者转为积极治疗,以全身治疗和手术为主。

核心结论

  • 大多数接受AS的患者疾病稳定或部分缓解,约三分之一转为积极治疗。

研究设计与样本

  • 系统文献综述,检索至2020年4月14日,纳入25篇描述AS结局的研究,遵循PRISMA指南。

主要发现

  • 诊断时中位年龄范围28至59岁,常见部位为四肢/肢带(n=273)、腹壁(n=253)和躯干(n=153)。
  • 报告的中位进展、稳定和部分缓解百分比分别为20%(IQR 13-35%)、59%(IQR 37-69%)和19%(IQR 3-23%)。
  • 640例患者结局未具体说明;报告的中位转为积极治疗百分比为29%,最常见为全身治疗(n=195)和手术(n=107)。
  • 报告的中位随访时间范围8至73个月,中位进展和/或启动转为积极治疗的时间范围6.3至19.7个月。

临床怎么用

  • AS可作为DTF一线管理策略,但需识别可能受益的患者。

局限性

  • 640例患者结局未具体说明,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study evaluates the results of the active surveillance (AS) approach in adult patients with desmoid-type fibromatosis (DTF) because AS is advocated as a front-line approach for DTF in the European consensus guidelines. METHODS: A systematic literature search was conducted (December 19th, 2019, updated on April 14th, 2020). Studies describing the outcomes of the AS approach were included. The PRISMA guidelines were used. RESULTS: Twenty-five articles were included for data retrieval. Forty-two percent of reported patients (1480 of 3527 patients) received AS, the majority were women and the majority had a primary tumour. The median age at diagnosis ranged from 28 to 59 years. Common tumour sites were the extremities/girdles (n = 273), the abdominal wall (n = 253) and the trunk (n = 153). The median reported percentage of progressive disease, stable disease and partial response was 20% (interquartile range [IQR]: 13-35%), 59% (IQR: 37-69%) and 19% (IQR 3-23%), respectively. In 640 patients, the outcome was not specified. The median reported percentage of shifting to an active form of treatment was 29%, most commonly to systemic treatment (n = 195) and surgery (n = 107). The reported median follow-up time ranged between 8 and 73 months. The reported median time to progression and/or initiation of the subgroup shifting from AS to 'active' therapy ranged from 6.3 months to 19.7 months. CONCLUSION: The majority of patients undergoing AS have either stable disease or a partial response, and about one-third of patients shift to an active form of treatment. Selecting patients who will benefit from active surveillance upfront should be the priority of future studies.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Timbergen MJM, Schut AW, Grünhagen DJ, et al. Active surveillance in desmoid-type fibromatosis: A systematic literature review. Eur J Cancer. 2020. PMID: 32738571. doi:10.1016/j.ejca.2020.06.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。